Trials / Completed
CompletedNCT00359177
Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Hepatic Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate how subjects with mild or moderate liver problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW679769 | GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2006-10-12
- Completion
- 2006-10-12
- First posted
- 2006-08-01
- Last updated
- 2017-09-25
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00359177. Inclusion in this directory is not an endorsement.